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Bone morphogenetic protein 2 (BMP2) 
induces growth suppression and enhances 
chemosensitivity of human colon cancer cells
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Abstract 
Background: Molecular profiling of colorectal cancer (CRC) based on global gene expression has revealed multiple 
dysregulated signalling pathways associated with drug resistance and poor prognosis. However, the role of BMP2 
signaling in CRC is not fully characterised.
Methods: Bioinformatics data analysis were conducted on the GSE21510 dataset. Leniviral technology was utilized 
to stably express BMP2 in the HCT116 CRC model. Gene expression profiling was conducted using Agilent microarray 
platform while data normalization and bioinformatics were conducted using GeneSpring software. Changes in gene 
expression were assessed using qRT‑PCR. AlamarBlue assay was used to assess cell viability in vitro. In vivo experi‑
ments were conducted using SCID mice.
Results: Our data revealed frequent downregulation of BMP2 in primary CRC tissues. Additionally, interrogation of 
publically available gene expression datasets revealed significant downregulation of BMP2 in metastatic recurrent 
compared to non‑metastatic cancer (p = 0.02). Global gene expression analysis in CRC cells over‑expressing BMP2 
revealed multiple dysregulated pathways mostly affecting cell cycle and DNA damage response. Concordantly, 
lentiviral‑mediated re‑expression of BMP2 inhibited HCT116 CRC growth, sphere formation, clonogenic potential, cell 
migration, and sensitized CRC cells to 5‑fluorouracil (5‑FU) in vitro. Additionally, BMP2 inhibited CRC tumor formation 
in SCID mice.
Conclusions: Our data revealed an inhibitory role for BMP2 in CRC, suggesting that restoration of BMP2 expression 
could be a potential therapeutic strategy for CRC.
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Background
Colorectal cancer (CRC) is the third most common can-
cer type globally with an annual incidence of over 1.2 
million new cases. It is also a leading cause of cancer-
related mortality, and accounts for  >600,000 cancer-
related deaths each year [1–3]. Traditionally, CRC has 
been classified based on standardized histopathological 
features; more recently, molecular genotyping has also 
been investigated. Both technologies revealed a complex 
and heterogeneous nature of CRC. Several pathological 
mechanisms and signalling pathways have been identified 
as contributing to the pathophysiology of this disease, 
and some of these mechanisms already operate in the 
precancerous lesions, which has been termed the com-
mon serrated tumour pathway [4]. Among these signal-
ling pathways, bone morphogenetic protein signalling is 
relevant [5].
Bone morphogenetic proteins (BMP) belong to the 
transforming growth factor beta superfamily (TGFβ) and 
are important regulators of embryogenesis, and pattern-
ing of body axes. They regulate adult tissue homeostasis 
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through control of cell growth, apoptosis and differen-
tiation. The biological effects of BMPs have been mostly 
studied in mesoderm-derived cells and tissues, and to 
lesser degree in epithelial cells and tissues. A number 
of studies have examined the association of abnormal 
BMP signalling with cancer initiation and/or progres-
sion. Changes in BMP signaling via the Smad cascade has 
been associated with a number of tumour types [6, 7]. 
Also, BMP-2, -4 and -7 have exhibited altered expression 
in many types of malignancies including breast, prostate, 
osteosarcoma, glioma, ovarian, pancreatic, lung, and 
other cancers.
Dysfunctional BMP signaling has been implicated in 
CRC. Mutations in BMP receptor 1A (BMPR1A) or its 
downstream effector SMAD4 have been identified in 
patients with juvenile polyposis (JP), a rare autosomal 
dominant hamartomatous polyposis syndrome with a 12 
fold increased lifetime risk for development of CRC [5]. 
BMP signaling molecules are expressed in human CRCs, 
and BMP signaling has been shown to induce growth 
suppression through the BMPR1A and intracellular 
SMAD pathway [8–10].
We have previously reported the global mRNA expres-
sion profiling in CRC tissues as compared to adjacent 
normal mucosa, and identified several dysregulated 
mRNAs including down regulation of BMP2 [2]. In the 
current study, we examined the biological role of BMP2 
in CRC. We employed lentiviral gene transfer technology 
to overexpress BMP2 in the human HCT116 CRC cell 
line, and examined its effects on cell proliferation, migra-
tion, clonogenic potential, drug resistance, and in  vivo 
tumour growth.
Methods
Cells lines and tissue culture
The human colorectal cancer (HCT116) cell line was 
obtained and subsequently was authenticated by Genet-
ica DNA Laboratories, Inc. Burlington, (NC, USA). Cells 
were maintained in DMEM supplemented with 10 % fetal 
bovine serum (Gibco-Invitrogen, Waltham, MA, USA) 
and 100  mg/l penicillin/streptomycin. All cells were 
maintained in a 37  °C incubator with humidified 5  % 
CO2.
Lentiviral transduction
Lentiviral particles encoding for LV BMP2 (LP-A0241-
Lv105-0200-P) or control lentiviral particles (LP-
EGFP-LV105-0200) were purchased from Genecopoeia 
(Genecopoeia Inc., Rockville, MD, USA). One hun-
dred fifty thousand HCT116 cells were seeded in com-
plete DMEM in 24-well plate. Twenty-four hours 
later (~80 confluency), media was removed and 
then 20  μl of crude lentiviral particles in 500  μl of 
DMEM  +  5  %  heat-inactivated serum (Invitrogen) and 
1  %  Pen–Strep supplemented with polybrene (8  μg/ml; 
Sigma, St. Louis, MO, USA) was added to the cells. Sev-
enty-two hours later, media was removed and transduced 
cells were selected with puromycin (1  μg/ml, Sigma, St. 
Louis, MO. USA) for 1  week or until stably transduced 
cells were generated.
Gene expression microarray
RNA isolation, gene and microRNA expression analysis 
were performed in accordance with our previously pub-
lished protocols [11]. In brief, RNA was isolated using 
Total RNA Purification Kit from Norgen-Biotek Corp. 
(Thorold, ON, Canada) and were quantified using Nan-
oDrop 2000 (Thermo Scientific, Wilmington, DE, USA). 
Total RNA was labelled and then hybridized to the Agi-
lent Human SurePrint G3 Human GE 8 ×  60  k mRNA 
microarray chip (Agilent Technologies). All microarray 
experiments were conducted at the Microarray Core 
Facility (Stem Cell Unit, College of Medicine, King Saud 
University). Data were subsequently normalized and ana-
lyzed using GeneSpring 13.0 software (Agilent Technolo-
gies). Pathway analyses were conducted using the Single 
Experiment Pathway analysis feature in GeneSpring 13.0 
(Agilent Technologies). The Benjamini-Hochberg false 
discovery rate (FDR) multiple testing correction method 
[p(corr)  <  0.02] was utilized and two fold cut-off were 
used to enrich for significantly changed transcripts.
mRNA validation by qRT‑PCR
mRNAs expression levels were validated in LV control 
and LV BMP2 HCT116 cells using SYBR Green-based 
qRT-PCR and the Applied Biosystems ViiA™ 7 Real-
Time PCR System. Two  μg of total RNA was reverse 
transcribed using High Capacity cDNA Reverse Tran-
script Kit (Part No: 4368814; ThermoFisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
protocol. Primer sequences used in the current study are 
listed in Table 1. The relative expression level was calcu-
lated using −ΔΔCT. GAPDH was used as an endogenous 
control.
Measurement of cell viability, clonogenic and sphere 
formation
The viability of LV control and LV BMP2 HCT116 cells 
was determined using alamarBlue assay as previously 
described [12]. All assays were carried out with appro-
priate controls. Briefly, 10,000 cells were cultured in 
a 96-well plate and cell viability was measured at the 
indicated time points by adding 10  % volume alamar-
Blue assay reagent and measuring absorbance at 570  λ. 
The colony forming ability of HCT116 cells transduced 
with BMP2 was determined using clonogenic assay 
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as previously described [12, 13]. Briefly, LV control or 
BMP2 HCT116 cells were seeded in 12-well plates in 
different serial dilution (1:2–1:64). Initial seeding den-
sity was 0.015  ×  106 cells per well, and incubated at 
37  °C under 5 % CO2 for 10 days. The plates were then 
washed and stained with Diff-Quik stain set (Siemens 
Healthcare Diagnostics), and the plates were scanned and 
number of colonies were observed under microscope. 
The fraction of surviving cells was estimated by compar-
ing BMP2 to LV control cells. The experiment was done 
twice in duplicate. Furthermore, the clonogenic assay 
was conducted to examine the effect of 5-fluorouracil 
on cell growth and proliferation in both cells. A total of 
1 × 106 cells were seeded in T25 flask. After 48 h of expo-
sure to 1.5  µM of 5-fluorouracil, the cells were trypsi-
nized and reseeded in 12-well plates as described above 
to observe the effect of the drug.
Multicellular tumor spheroids were produced in 60 mm 
low cell binding dishes (Nunc; ThermoFisher Scientific). 
LV control or BMP2 HCT116 cells were trypsinized 
from monolayers and transferred to the low cell binding 
dishes. The formation of tumor spheroids was performed 
with 10,000 cells. On day 10, established spheroids were 
analysed.
Cell migration and proliferation
Real-time measurement of LV control and BMP2 
HCT116 cell migration and proliferation was executed 
using the xCELLigence RTCA DP device (ACEA Bio-
sciences, San Diego, CA). For migration study, cells were 
starved for 24 h in 1 % serum media, followed by seed-
ing 0.08 ×  106 cells per well in 16-well microelectronic 
sensor plate pre-coated with fibronectin (1:500), two 
chamber trans-well plates (CIM-plate insert; ACEA 
Bioscience) containing the respective serum conditions. 
Medium containing 10 % serum (chemo-attractant) and 
1  % serum (negative control) was added to the bottom 
wells.
For proliferation assay, cells were seeded 
(0.04  ×  106  cells/well) in two chamber plates (E-plate 
insert; ACEA Bioscience). Proliferation and migration 
of cells was measured from the interaction of cells with 
the electrodes on the bottom surface of top chamber and 
represented as a change in cell index (CI). The electrical 
impedance was captured every 15 min for an experimen-
tal duration of ~68  h. The rate of migration and prolif-
eration is expressed as the CI or the change in electrical 
impedance at each time-point. The Cell Index at each 
time point is defined as (Rn-Rb)/4.6, where Rn is the cell-
electrode impedance of the well when it contains cells 
and Rb is the background impedance of the well with the 
media alone. Values are expressed as the mean ± SEM of 
the 3 replica wells.
For conventional migration, the BD transwell migra-
tion system with 8 µ pore size was utilized as previously 
described [14]. Inserts were placed in a 24-well plate, and 
1.56 × 105 cells in 1 % serum were added to the top of the 
chamber, and 10 % serum added to the bottom chamber. 
Hundred hours later, inserts were fixed and stained with 
SIEMENNS DIFF-QUICK stain set (Siemens Health-
care Diagnostics), and the number of migrating cells was 
counted using a light microscope.
Table 1 List of CYBR green primers used in current study
No Name Sequence
1 CASP10 F 5′ GAAGCCTTACCGCAGGAGTC 3′
R 5′ GTGCACCATTTGTGGCTCTG 3′
2 HDAC4 F 5′ ACTGGTACGGGAAAACGCAG 3′
R 5′ TTTGGCGTCGTACATTCCCA 3′
3 MAPK9 F 5′ TGGGCTACAAAGAGAACGTTGAT 3′
R 5′ AAGGTCGCGGGGAAGGATA 3′
4 MDM2 F 5′ AGGAGATTTGTTTGGCGTGC 3′
R 5′ TGAGTCCGATGATTCCTGCTG 3′
5 WNT7A F 5′ ATGCCCGGACTCTCATGAAC 3′
R 5′ GTTCTCCTCCAGGATCTTTCGG 3′
6 WNT3 F 5′ GGACAAAGCTACCAGGGAGT 3′
R 5′ CTGCACATGAGCGTGTCACT 3′
7 WNT4 F 5′ CATGAGTCCCCGCTCGTG 3′
R 5′ CCAGGTACAGCCAGTTGCTC 3′
8 SMAD4 F 5′ GGATACGTGGACCCTTCTGG 3′
R 5′ TGTGCAACCTTGCTCTCTCAA 3′
9 TERT F 5′ GGCACGGCTTTTGTTCAGAT 3′
R 5′ TCCGGGCATAGCTGGAGTAG 3′
10 AFT3 F 5′ GTGAGTCCTCGGTGCTCG 3′
R 5′ GCATCATTTTGCTCCAGGCT 3′
11 HOMEZ F 5′ CTGGACTGCGCTATCTCTGAAG 3′
R 5′ TGAACTACTGAGACCGCTGG 3
12 FADD F 5′ GGGAAGAAGACCTGTGTGCAG 3′
R 5′ GAGCCAGCCTTCTCCAATCT 3′
13 BCL2 F 5′ AGATTGATGGGATCGTTGCCT 3′
R 5′ AGTCTACTTCCTCTGTGATGTTGT 3′
14 BIRC5 F 5′ AGCCAAGAACAAAATTGCAAAGG 3′
R 5′ CGCACTTTCTCCGCAGTTTC 3′
15 E2F1 F 5′ AACTGACCATCAGTACCTGGC 3′
R 5′ GGGATTTCACACCTTTTCCTGG 3′
16 E2F2 F 5′ AGGAGCAGACAGTGATTGCC 3′
R 5′ GGTTGTCCTCAGTCCTGTCG 3′
17 BMP2 F 5′ GGAACGGACATTCGGTCCTT 3′
R 5′ CACCATGGTCGACCTTTAGGA 3′
18 GAPDH F 5′ CTGGTAAAGTGGATATTGTTGCCAT 3′
R 5′ TGGAATCATATTGGAACATGTAAACC 3′
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Measurement of apoptosis
Fluorescence-based apoptosis was determined in cells 
after exposure to different concentration of 5-fluoroura-
cil, using acridine orange and ethidium bromide (AO/
Etbr) staining method. After treatment, the LV control 
and BMP2 HCT116 cells were stained with dual fluores-
cent staining solution (1 µl) containing 100 µg/ml AO and 
100 µg/ml EB (AO/EB, Sigma, St. Louis, MO). Cells were 
washed twice with PBS and were gently mixed with AO/
EB (1:100) dye solution for 1  min; afterwards, the cells 
were observed and photographed under a Nikon Eclipse 
Ti fluorescence microscope. Cells cultured without drug 
were considered as experiment control. Acridine Orange/
Ethidium Bromide Staining uses combination of two dyes 
to visualize cells with aberrant chromatin organization. 
The differential uptake of AO/EB allows the identifica-
tion of viable and non-viable cells. Particularly, Acridine 
Orange was used to visualize the number of cells which 
has undergone apoptosis.
In vivo tumorigenicity assay in SCID mice
In vivo tumor formation was carried out as previously 
described [15]. Briefly, 6- to 8-week-old severe combined 
immunodeficient (SCID) mice were utilized for the xeno-
graft experiments. Ten million LV control or LV BMP2 
HCT116 cells were suspended in PBS and subcutaneously 
injected into the right flank of SCID mice. Tumor volume 
was measured twice  weekly using a caliper, and tumor 
volume was calculated as (tumor length × width2)/2. At 
the end of the experiment, tumors were excised, fixed in 
10  % buffered formalin, and embedded in paraffin and 
sectioned. Sections were the stained with haematoxylin 
and eosin.
Immunohistochemistry
We used commercially available anti-bcl-2 (124) 
mouse monoclonal primary antibody (790-4464; Ven-
tana; Roche) and anti-Ki67 antibody rabbit polyclonal 
(ab15580; Abcam) in 1:200 dilution to stain the tumor 
section. Four-micron-thick sections were immunostained 
for Bcl-2 and Ki67 protein using the immunohistochemi-
cal (IHC) staining protocol optimized in King Khalid uni-
versity hospital, King Saud University, Riyadh. The IHC 
staining was carried out using a BenchMark XT fully 
automated IHC/ISH staining instrument (Ventana Medi-
cal system Inc, Tucson, Arizona, USA), as per manufac-
turer’s protocol using proprietary reagents. Briefly, slides 
were deparaffinized on the automated system with EZ 
Prep solution (Ventana). Enzymatic retrieval was used 
with protease 1 solution (Ventana). The detection sys-
tem used was the ultraView Universal DAB Detection Kit 
(760-500; Ventana; Roche), and slides were then counter-
stained with hematoxylin and mounted.
Statistical analysis
Statistical analyses and graphing were performed using 
Microsoft Excel 2010 and GraphPad Prism 6.0 software 
(GraphPad, San Diego, CA, USA). P values were calcu-
lated using the two-tailed t test.
Results
BMP2 is downregulated in CRC and its overexpression 
reduces HCT116 cell growth, migration, sphere formation 
and colony formation
Global mRNA gene expression profiling of CRC tissue 
and adjacent normal mucosa revealed decreased levels 
of BMP-2 gene expression (Fig. 1a) [2]. Follow up bioin-
formatics analysis of CRC gene expression data using 
the GEO database (GSE21510) revealed similar pattern 
of down regulation of BMP-2 gene expression in CRC 
compared to normal tissues, and this was also observed 
in metastatic and metastatic recurrent CRC lesions, sug-
gesting that loss of BMP2 is an unfavourable event in CRC 
pathogenesis and progression (Fig.  1b). Lentiviral-medi-
ated stable overexpression of BMP2 reduced viability of 
HCT116 CRC cells in vitro (Fig. 1c, d). Adding exogenous 
recombinant BMP2 to HCT116 cells led to similar results 
(Additional file 1: Figure S1). Concordantly, real time pro-
liferation assay revealed striking decrease in the prolifera-
tion of LV-BMP2-HCT116 cells compared to LV control 
cells in a time dependent manner (Fig. 1e). Similar inhibi-
tory effects were also observed on cell migration toward 
media containing 10  % FBS in the LV-BMP2-HCT116 
compared to LV control cells employing two independent 
assays: transwell migration assay (Fig. 1f ) and microelec-
tronic sensor plate assay (Fig.  1g), implicating a role for 
BMP2 in proliferation as well as in migration.
In agreement with proliferation data, the clonogenic 
assay revealed fewer colonies in the LV-BMP2-HCT116 
compared to LV control cells (Fig.  2a), suggesting an 
inhibitory effect of BMP2 on colony forming unit in the 
HCT116 model. We subsequently assessed the ability of 
those cells to form spheres when cultured in low adher-
ence plates. The control tumor formed spheres with 
compact and clear rounded edges, while the LV-BMP2 
tumour-derived spheres were less compact and have 
irregular edges (Fig. 2b).
Dysregulated genetic pathways in LV‑BMP2‑HCT116 cells
To unravel the molecular processes regulated by BMP2, 
we performed global mRNA expression profiling on 
LV-BMP2-HCT116 and LV-Control cells. As shown in 
Fig.  3a, hierarchical clustering based on differentially-
expressed mRNAs revealed clear separation between the 
two groups. We identified 11,950 differentially-expressed 
transcripts in LV-BMP2-HCT116 cells [>2.0 fold change 
(FC), p(corr)  <  0.02; Additional file  2: Table S1]. The 
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Fig. 1 BMP2 is downregulated in CRC and it suppresses CRC cell proliferation and migration. a Expression of BMP2 in CRC (Log2) compared to adja‑
cent normal tissue based on microarray data. Data are presented as mean ± S.E., n = 13. b Expression of BMP2 in control (n = 25), non‑recurrent 
(n = 76), metastatic (n = 23), and metastatic recurrent (n = 24) from the GSE21510 CRC dataset. c qRT‑PCR quantification of BMP2 expression in 
BMP2 HCT116 compared to LV control cells. Data are presented as mean ± S.D., n = 3. d Lentiviral‑mediated re‑expression of BMP2 in HCT116 cells 
reduces their cell viability. e Real time proliferation assay revealed significant decrease in the proliferation of BMP2 HCT116 compared to LV control 
cells in a time‑dependent manner. f, g Conventional and real time migration assay showing significant inhibition of cell migration in the BMP2 
HCT116 compared to LV control cells. The two‑tailed t‑test was used to compare different treatment groups. ***p < 0.0005
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distribution of the top 10 enriched pathways of the dif-
ferentially-expressed genes in LV-BMP2-HCT116 cells 
are shown in Fig. 3b, which included cell cycle, DNA rep-
lication, and DNA damage response pathways. Illustra-
tion of the cell cycle pathway is presented in panel Fig. 3c 
and Additional file 3: Figure S2. We validated the expres-
sion level of a panel of selected genes using qRT-PCR: 
CASP10, HADAC4, WNT3, MAPK9, MDM2, WNT7A, 
WNT3A, WNT4, SMAD4, TERT, AFT3, HOMEZ, 
FADD, BCL2 and E2F2 (Fig. 3d).
Fig. 2 BMP2 reduces CRC colony and sphere formation in vitro. a Clonogenic assay showing remarkable reduction in the colony forming capability 
of BMP2 HCT116 cells compared to LV control cells. Plates were stained with Diff‑Quik stain set on day 10. Wells are representative of two independ‑
ent experiments for each condition. b Inhibition of sphere formation by BMP2 in the HCT116 CRC model
(See figure on next page.) 
Fig. 3 BMP2 regulated multiple cellular processes in HCT116 cells. a Hierarchical clustering of BMP2 HCT116 vs LV control HCT116 cells based on 
differentially expressed mRNA levels. Each column represents one replica and each row represents a transcript. Expression level of each gene in a 
single sample is depicted according to the colour scale. b Pie chart illustrating the distribution of the top 10 pathway designations for the differen‑
tially expressed genes in BMP2 HCT116 cells. The pie size corresponds to the number of matched entities. c The cell cycle pathway is illustrated in 
panel c. d The expression levels of selected genes from the microarray data were validated using qRT‑PCR in BMP2 HCT116 cells. Data are presented 
as mean ± S.D, n = 3
Page 7 of 12Vishnubalaji et al. Cancer Cell Int  (2016) 16:77 
Page 8 of 12Vishnubalaji et al. Cancer Cell Int  (2016) 16:77 
BMP2 increases CRC cell sensitivity to 5‑fluorouracil
Pathway analysis of differentially-expressed genes in LV-
BMP2-HCT116 cells revealed enrichment in genes asso-
ciated with response to DNA damage (Fig. 3b), suggesting 
that BMP2 may sensitize cancer cells to DNA damage-
inducing agents. Illustration of the DNA damage response 
pathway is presented in Fig. 4a and Additional file 4: Fig-
ure S3. To test this hypothesis, LV-BMP2-HCT116 and LV 
control HCT116 cells were incubated in the presence of 
5-FU (1.5–100 μM), then assessed for apoptotic/necrotic 
response. 5-FU concentrations exceeding  >3.1  µM were 
highly toxic; whilst lower concentrations (<3.1  µM) 
induced more apoptosis in the BMP2-HCT116 com-
pare to LV Control HCT116 cells on day 5 (Fig.  4b). As 
expected, fewer colonies were observed in the LV-BMP2-
HCT116 cells in the presence of 5-FU (1.5 μM) compared 
to LV control-HCT116 cells (Fig. 4c).
BMP2 suppresses tumor growth in vivo
To further understand the biological significance of 
BMP2 on CRC tumorogenesis in  vivo, LV-BMP2-
HCT116 or LV control HCT116 cells were implanted 
subcutaneously into immune deficient SCID mice, and 
the volume of formed tumors was subsequently deter-
mined. Significant reduction in tumor growth was 
observed for the LV-BMP2-HCT116 tumours, cor-
roborating the in vitro inhibitory observations of BMP2 
(Fig. 5a). Histological examination of tumor xenograft tis-
sues revealed a higher degree of cell death (necrosis and 
apoptosis), and a reduced frequency of mitotic events in 
the LV-BMP2-HCT116 group (Fig. 5b).
Discussion
Identifying signalling pathways that are associated with 
cancer is important in order to identify novel targets for 
therapy. In the current study, we have demonstrated that 
enhanced expression of BMP2 in CRC cells reduced their 
growth, enhanced apoptosis and decreased tumor devel-
opment in  vivo. Given our previous demonstration that 
CRCs expressed lower levels of BMP2 [2]; the more pro-
nounced downregulation of BMP2 in metastatic-recur-
rent patients from the GSE21510, combined with the 
current data, this all indicate that BMP2 and BMP signal-
ling are important regulators of CRC development and 
progression. Although the exact molecular mechanism 
leading to BMP2 downregulation in CRC is still 
unknown, genomic deletion, DNA methylation or epi-
genetic regulation could potentially play a role in BMP2 
downregulation in CRC. Downregulation of BMP2 was 
also observed in several CRC cell lines (Additional file 5: 
Figure S4).
We employed HCT116 as a cell model for CRC; over-
expression of BMP2 inhibited CRC proliferation, migra-
tion, colony and spheroid formation and in  vivo tumor 
growth, demonstrating a tumor suppressive role for 
BMP2. Restitution of BMP2 expression also restored 
sensitivity to 5-FU. Molecular signature of HCT116 cells 
overexpressing BMP2 revealed multiple altered genetic 
pathways including cell cycle, DNA replication, DNA 
damage response, and WNT signalling, which could pro-
vide the biological explanations for the observed associa-
tion between BMP2 status and CRC. Interestingly, our 
recent data revealed a significant role for TGF-beta in 
CRC, as pharmacological inhibition of TGF-beta path-
way inhibited CRC growth in  vitro [2]. Similar to our 
findings, Zhang et al. also recently reported an inhibitory 
role for BMP2 in governing the proliferation and aggres-
sive behavior of human CRC cells [16].
Genetic studies showed mutations in the TGF-β sign-
aling pathway to increase the mortality risk in CRC 
patients [17]. Additionally, a number of other studies 
have reported that BMP2 expression is dysregulated 
in CRC. BMPR1a, BMPR1b, BMPR2, phosphorylated 
Smad1, and Smad4 are expressed  in  mature  colon cells 
in normal adult human and mouse colon [8]. Several 
members of the BMP family (BMP2, BMP3 or BMP7) 
are downregulated in CRC, and have been shown to pro-
mote apoptosis, differentiation, and inhibit proliferation 
[8–10, 16]. Our study corroborates these findings; iden-
tifying a specific role for BMP2 in CRC. Furthermore, we 
provide evidence suggesting that targeting BMP2 signal-
ling could be a possible approach to limit CRC tumour 
growth.
While our study suggest a suppressive role for BMP2 in 
CRC, the precise role for the BMP signalling in tumour 
development is controversial since it has been reported 
to either promote or inhibit tumorogenesis [7]. Therefore 
it is possible that the effect of BMP signalling is depend-
ent on tumour type as well as the status of other pathways 
in different cancers. For example, Alarmo et al. reported 
(See figure on next page.) 
Fig. 4 BMP2 sensitize CRC cells to 5‑fluorouracil. a Illustration of the DNA damage response pathway based on microarray data with matched enti‑
ties highlighted. b Representative fluorescence images of BMP2 and LV control HCT116 cells [±different concentration (1.5–100 μM) 5‑fluorouracil]. 
Cells were stained with acridine orange/ethidium bromide to detect apoptotic (cells with green condensed chromatin) and necrotic cells (red) c. 
Representative clonogenic assay showing reduced clonogenicity of BMP2 HCT116 compared to LV control HCT116 cells (±1.5 μM 5‑fluorouracil). 
Plates were stained with Diff‑Quik stain set on day 10
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Fig. 5 BMP2 expression suppresses CRC growth in vivo. a Tumour formation in SCID mice after subcutaneous injection of HCT116 cells stably‑
expressing BMP2 or LV control cells. Data are presented as mean (tumor volume) ± S.E., n = 6. Two‑way ANONA analysis was used to compare 
the two growth curves. b Representative histopathological examination of xenograft tumors from BMP2 and control HCT116 cells. FFPE sections 
were stained with haematoxylin and eosin stain. (Bar = 100 μm). Expression of MKI67 (c) and BCL2 (d) in xenograft tumors from BMP2 and control 
HCT116 cells is shown
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that BMP7 can either promote or inhibit carcinogenesis, 
depending on dose, type of cell or tissue origin, and the 
environmental niche, reflecting the complexity of net-
works and pathways involved in cancer development and 
progression [18].
Conclusions
We propose that loss of BMP2 leads to deregulation in 
multiple signaling pathways involving cell cycle, DNA 
replication, and DNA damage response resulting in CRC 
development, progression and possibly resistance to 
chemotherapy. Targeting the BMP2 pathway may there-
fore offer potential therapeutic benefit in CRC therapy.
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